Candoxatril increased exercise tolerance and reduced symptoms in a study involving 59 patients with mild congestive heart failure (CHF). This is thought to be the first study to demonstrate the effects of a neutral endopeptidase inhibitor on CHF symptoms. The results, which were presented at Heart Failure '95 [Amsterdam, The Netherlands; April 1995], led researchers to say that candoxatril could be used as first-line therapy in mild CHF, or as adjunctive therapy in more severe cases of disease.